Topas Therapeutics
PrivateLast Round
Series B
Jul 29, 2021
Total Funding Raised
$138M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Topas Therapeutics is a biotechnology company that develops nanoparticle-based therapeutics to induce antigen-specific immune tolerance for the treatment of autoimmune diseases, allergies, and anti-drug antibodies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Topas Therapeutics Comparables
Compare Topas Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Anokion | 90% | |
| Imcyse | 86% | |
| Cour Pharma | 85% |
Topas Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jul 29, 2021 | ||||
| Series B | Oct 19, 2020 | ||||
| Series A | Nov 2, 2017 | ||||
| Series A | Mar 22, 2016 |
Key People
Founding team and executive leadership
Topas Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BioMedPartners | Series B |
| Gimv | Series A, Series B |
| Epidarex Capital | Series A, Series B |
| Vesalius Biocapital Partners | Series B |
| Boehringer Ingelheim Venture Fund | Series A, Series B |
| EMBL Ventures | Series A, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 18, 2026
Presenting at BioCentury's Grand Rounds Europe on September 18, 2026.
- Oct 6, 2025
Presented new Phase 2a data for TPM502 at UEG Week.
Topas Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Topas Therapeutics's valuation, stock price, and market status.
Is Topas Therapeutics a public or private company?
Topas Therapeutics is a private company.
What is the current stock price of Topas Therapeutics?
Topas Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Topas Therapeutics worth (valuation)?
Valuation information for Topas Therapeutics is not publicly available.
Can I buy Topas Therapeutics stock?
Topas Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Topas Therapeutics's last funding round?
Topas Therapeutics's most recent funding round was Series B Extension on July 29, 2021.
Who are the main investors in Topas Therapeutics?
Key investors in Topas Therapeutics include BioMedPartners, Epidarex Capital, Vesalius Biocapital Partners.
Will Topas Therapeutics IPO soon?
No public IPO plans have been announced for Topas Therapeutics.
How can I track Topas Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Topas Therapeutics's secondary market activity and sign up for updates.